An ANOCEF genomic and transcriptomic microarray study of the response to irinotecan and bevacizumab in recurrent glioblastomas

BioMed Research International

Volumn 2014, Issue , 2014, Pages

  Laffaire, Julien ^a   Stefano, Anna Luisa Di ^b,c,d   Chinot, Olivier ^e,f,g   Idbaih, Ahmed ^b,c,g   Gallego Perez Larraya, Jaime ^b,c,g   Marie, Yannick ^b,c   Vintonenko, Nadia ^b,c   Boisselier, Blandine ^b,c   Farina, Patrizia ^b,c,h   Delattre, Jean Yves ^b,c,g   Figarella Branger, Dominique ^e,f,g   Honnorat, Jérôme ^g,i,j,k   Sanson, Marc ^b,c,g   Ducray, François ^g,i,j,k  

^a Programme Cartes d'Identite des Tumeurs CIT   (France)

^b PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^c INSTITUT DU CERVEAU ET DE LA MOELLE ÉPINIÈRE   (France)

^d C MONDINO NATIONAL NEUROLOGICAL INSTITUTE   (Italy)

^e TIMONE HOSPITAL   (France)

^f University of the Mediterranean Aix Marseille II   (France)

^g ANOCEF (Assoc des Neuro Oncologues d'Expression Francaise (Fr Speaking NeuroOncologists' Assoc))   (France)

^h VENETO INSTITUTE OF ONCOLOGY IOV IRCCS   (Italy)

ⁱ HÔPITAL NEUROLOGIQUE   (France)

^j UNIVERSITÉ DE LYON   (France)

^k LYON NEUROSCIENCE RESEARCH CENTER   (France)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; CYCLIN DEPENDENT KINASE INHIBITOR 2A; EPIDERMAL GROWTH FACTOR RECEPTOR; IRINOTECAN; ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; CAMPTOTHECIN; MONOCLONAL ANTIBODY; TRANSCRIPTOME;

ADULT; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER RECURRENCE; CLINICAL ARTICLE; CONTROLLED STUDY; GENE DELETION; GENE EXPRESSION PROFILING; GENETIC ASSOCIATION; GENOME ANALYSIS; GENOMICS; GLIOBLASTOMA; HUMAN; MICROARRAY ANALYSIS; OUTCOME ASSESSMENT; RETROSPECTIVE STUDY; TRANSCRIPTOMICS; TREATMENT RESPONSE; ANALOGS AND DERIVATIVES; BRAIN NEOPLASMS; CLINICAL TRIAL; COMPARATIVE STUDY; DNA MICROARRAY; DRUG EFFECTS; FEMALE; GENE EXPRESSION REGULATION; MALE; METABOLISM; MIDDLE AGED; MULTICENTER STUDY; NEOPLASM RECURRENCE, LOCAL;

ADULT; AGED; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS, PHYTOGENIC; BRAIN NEOPLASMS; CAMPTOTHECIN; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GLIOBLASTOMA; HUMANS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; RETROSPECTIVE STUDIES; TRANSCRIPTOME;

EID: 84899569554     PISSN: 23146133     EISSN: 23146141     Source Type: Journal    
DOI: 10.1155/2014/282815     Document Type: Article

References (27)

1. Friedman H. S., Prados M. D., Wen P. Y., Mikkelsen T., Schiff D., Abrey L. E., Yung W. K. A., Paleologos N., Nicholas M. K., Jensen R., Vredenburgh J., Huang J., Zheng M., Cloughesy T., Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. Journal of Clinical Oncology 2009 27 28 4733 4740 2-s2.0-70350461699 10.1200/JCO.2008.19.8721
2. Kreisl T. N., Kim L., Moore K., Duic P., Royce C., Stroud I., Garren N., Mackey M., Butman J. A., Camphausen K., Park J., Albert P. S., Fine H. A., Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma. Journal of Clinical Oncology 2009 27 5 740 745 2-s2.0-59949083263 10.1200/JCO.2008.16.3055
3. Vredenburgh J. J., Desjardins A., Herndon J. E. II, Marcello J., Reardon D. A., Quinn J. A., Rich J. N., Sathornsumetee S., Gururangan S., Sampson J., Wagner M., Bailey L., Bigner D. D., Friedman A. H., Friedman H. S., Bevacizumab plus irinotecan in recurrent glioblastoma multiforme. Journal of Clinical Oncology 2007 25 30 4722 4729 2-s2.0-36049037819 10.1200/JCO.2007.12.2440
4. Louis D. N., Ohgaki H., Wiestler O. D., The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathologica 2007 114 97 109
5. Stupp R., Mason W. P., van den Bent M. J., Weller M., Fisher B., Taphoorn M. J. B., Belanger K., Brandes A. A., Marosi C., Bogdahn U., Curschmann J., Janzer R. C., Ludwin S. K., Gorlia T., Allgeier A., Lacombe D., Cairncross J. G., Eisenhauer E., Mirimanoff R. O., Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. The New England Journal of Medicine 2005 352 10 987 996 2-s2.0-20044366163 10.1056/NEJMoa043330
6. Wen P. Y., Macdonald D. R., Reardon D. A., Cloughesy T. F., Sorensen A. G., Galanis E., DeGroot J., Wick W., Gilbert M. R., Lassman A. B., Tsien C., Mikkelsen T., Wong E. T., Chamberlain M. C., Stupp R., Lamborn K. R., Vogelbaum M. A., Van Den Bent M. J., Chang S. M., Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group. Journal of Clinical Oncology 2010 28 11 1963 1972 2-s2.0-77951625266 10.1200/JCO.2009.26.3541
7. Verhaak R. G. W., Hoadley K. A., Purdom E., Wang V., Qi Y., Wilkerson M. D., Miller C. R., Ding L., Golub T., Mesirov J. P., Alexe G., Lawrence M., O'Kelly M., Tamayo P., Weir B. A., Gabriel S., Winckler W., Gupta S., Jakkula L., Feiler H. S., Hodgson J. G., James C. D., Sarkaria J. N., Brennan C., Kahn A., Spellman P. T., Wilson R. K., Speed T. P., Gray J. W., Meyerson M., Getz G., Perou C. M., Hayes D. N., Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell 2010 17 1 98 110 2-s2.0-73649123907 10.1016/j.ccr.2009.12.020
8. Gravendeel L. A. M., Kouwenhoven M. C. M., Gevaert O., De Rooi J. J., Stubbs A. P., Duijm J. E., Daemen A., Bleeker F. E., Bralten L. B. C., Kloosterhof N. K., De Moor B., Eilers P. H. C., Van Der Spek P. J., Kros J. M., Sillevis Smitt P. A. E., Van Den Bent M. J., French P. J., Intrinsic gene expression profiles of gliomas are a better predictor of survival than histology. Cancer Research 2009 69 23 9065 9072 2-s2.0-71549126830 10.1158/0008-5472.CAN-09-2307
9. Irizarry R. A., Bolstad B. M., Collin F., Cope L. M., Hobbs B., Speed T. P., Summaries of Affymetrix GeneChip probe level data. Nucleic Acids Research 2003 31 4, article e15 2-s2.0-12344280017
10. Ducray F., de Reyniès A., Chinot O., Idbaih A., Figarella-Branger D., Colin C., Karayan-Tapon L., Chneiweiss H., Wager M., Vallette F., Marie Y., Rickman D., Thomas E., Delattre J., Honnorat J., Sanson M., Berger F., An ANOCEF genomic and transcriptomic microarray study of the response to radiotherapy or to alkylating first-line chemotherapy in glioblastoma patients. Molecular Cancer 2010 9, article 234 2-s2.0-77956474812 10.1186/1476-4598-9-234
11. Kapp A. V., Tibshirani R., Are clusters found in one dataset present in another dataset? Biostatistics 2007 8 1 9 31 2-s2.0-33845438621 10.1093/biostatistics/kxj029
12. Peiffer D. A., Le J. M., Steemers F. J., Chang W., Jenniges T., Garcia F., Haden K., Li J., Shaw C. A., Belmont J., Sau W. C., Shen R. M., Barker D. L., Gunderson K. L., High-resolution genomic profiling of chromosomal aberrations using Infinium whole-genome genotyping. Genome Research 2006 16 9 1136 1148 2-s2.0-33748272115 10.1101/gr.5402306
13. Staaf J., Vallon-Christersson J., Lindgren D., Juliusson G., Rosenquist R., Höglund M., Borg Å., Ringnér M., Normalization of Illumina Infinium whole-genome SNP data improves copy number estimates and allelic intensity ratios. BMC Bioinformatics 2008 9, article 409 2-s2.0-54949156063 10.1186/1471-2105-9-409
14. Venkatraman E. S., Olshen A. B., A faster circular binary segmentation algorithm for the analysis of array CGH data. Bioinformatics 2007 23 6 657 663 2-s2.0-34147104969 10.1093/bioinformatics/btl646
15. Popova T., Manié E., Stoppa-Lyonnet D., Rigaill G., Barillot E., Stern M. H., Genome Alteration Print (GAP): a tool to visualize and mine complex cancer genomic profiles obtained by SNP arrays. Genome Biology 2009 10 11, article R128 2-s2.0-76249097734 10.1186/gb-2009-10-11-r128
16. Idbaih A., Marie Y., Lucchesi C., Pierron G., Manié E., Raynal V., Mosseri V., Hoang-Xuan K., Kujas M., Brito I., Mokhtari K., Sanson M., Barillot E., Aurias A., Delattre J., Delattre O., BAC array CGH distinguishes mutually exclusive alterations that define clinicogenetic subtypes of gliomas. International Journal of Cancer 2008 122 8 1778 1786 2-s2.0-40349089779 10.1002/ijc.23270
17. Leslie-Barbick J. E., Shen C., Chen C., West J. L., Micron-scale spatially patterned, covalently immobilized vascular endothelial growth factor on hydrogels accelerates endothelial tubulogenesis and increases cellular angiogenic responses. Tissue Engineering A 2011 17 1-2 221 229 2-s2.0-78650879483 10.1089/ten.tea.2010.0202
18. Pal S., Datta K., Khosravi-Far R., Mukhopadhyay D., Role of protein kinase Czeta in Ras-mediated transcriptional activation of vascular permeability factor/vascular endothelial growth factor expression. The Journal of Biological Chemistry 2001 276 4 2395 2403 2-s2.0-0035951830 10.1074/jbc.M007818200
19. Carlson M. R. J., Pope W. B., Horvath S., Braunstein J. G., Nghiemphu P., Tso C., Mellinghoff I., Lai A., Liau L. M., Mischel P. S., Dong J., Nelson S. F., Cloughesy T. F., Relationship between survival and edema in malignant gliomas: role of vascular endothelial growth factor and neuronal pentraxin 2. Clinical Cancer Research 2007 13 9 2592 2598 2-s2.0-34249014416 10.1158/1078-0432.CCR-06-2772
20. Kumar A., Hou X., Lee C., Li Y., Maminishkis A., Tang Z., Zhang F., Langer H. F., Arjunan P., Dong L., Wu Z., Zhu L. Y., Wang L., Min W., Colosi P., Chavakis T., Li X., Platelet-derived growth factor-DD targeting arrests pathological angiogenesis by modulating glycogen synthase kinase-3 β phosphorylation. The Journal of Biological Chemistry 2010 285 20 15500 15510 2-s2.0-77952056907 10.1074/jbc.M110.113787
21. Li H., Adachi Y., Yamamoto H., Min Y., Ohashi H., Ii M., Arimura Y., Endo T., Lee C., Carbone D. P., Imai K., Shinomura Y., Insulin-like growth factor-I receptor blockade reduces tumor angiogenesis and enhances the effects of bevacizumab for a human gastric cancer cell line, MKN45. Cancer 2011 117 14 3135 3147 2-s2.0-79959990517 10.1002/cncr.25893
22. Mense S. M., Sengupta A., Zhou M., Lan C., Bentsman G., Volsky D. J., Zhang L., Gene expression profiling reveals the profound upregulation of hypoxia-responsive genes in primary human astrocytes. Physiological Genomics 2006 25 3 435 449 2-s2.0-33646765735 10.1152/physiolgenomics.00315.2005
23. Lombardi G., Zustovich F., Farina P., Hypertension as a biomarker in patients with recurrent glioblastoima treated with antiangiogenic drigs: a single-center experience and a critical review of the literature. Anticancer Drugs 2013 24 90 97
24. Tabouret E., Boudouresque F., Barrie M., Association of matrix metalloproteinase 2 plasma level with response and survival in patients treated with bevacizumab for recurrent high-grade glioma. Neuro-Oncology 2014 16 392 399
25. Ellingson B. M., Sahebjam S., Kim H. J., Pretreatment ADChistogram analysis is a predictive biomarker for bevacizumab treatment but not chemotherapy in recurrent glioblastoma. American Journal of Neuroradiology 2013 10.3174/ajnr.A3748
26. Sathornsumetee S., Cao Y., Marcello J. E., Herndon J. E. II, McLendon R. E., Desjardins A., Friedman H. S., Dewhirst M. W., Vredenburgh J. J., Rich J. N., Tumor angiogenic and hypoxic profiles predict radiographic response and survival in malignant astrocytoma patients treated with bevacizumab and irinotecan. Journal of Clinical Oncology 2008 26 2 271 278 2-s2.0-38349155463 10.1200/JCO.2007.13.3652
27. Erdem-Eraslan L., Gravendeel L. A., de Rooi J., Intrinsic molecular subtypes of glioma are prognostic and predict benefit from adjuvant procarbazine, lomustine, and vincristine chemotherapy in combination with other prognostic factors in anaplastic oligodendroglial brain tumors: a report from EORTC study 26951. Journal of Clinical Oncology 2013 31 328 336